Fig. 6. Uptake of anti-ICAM-1 or anti-PECAM-1 immunobeads is PKC-mediated. TNF--activated HUVEC were treated for 30 minutes with vehicle alone (A), 0.1 µM PMA (B), 0.1 µM BIM-1 (C) or 10 µM H-7 (D), then incubated with anti-ICAM-1 or anti-PECAM-1 immunobeads for 1 hour at 37°C, then fixed and immunostained to double-label surface-bound material (yellow, arrowheads). Arrows denote internalized immunobeads. Uptake of anti-ICAM-1 and anti-PECAM-1 immunobeads was quantified as mean±s.d. by fluorescence microscopy for these treatments, expressed as a percentage of immunobead uptake for the PKC inhibitors (E). For PMA, this is expressed as the total number of internalized particles per cell (F), as the percent internalization was equivalent for control and PMA stimulated cells. *P<0.05.

Return to article